Why Esperion Therapeutics (ESPR) Is Up After $75M Equity Raise and Generic Settlement News [Yahoo! Finance]
Esperion Therapeutics, Inc. (ESPR)
Last esperion therapeutics, inc. earnings: 2/27 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.esperion.com
Company Research
Source: Yahoo! Finance
stock at US$2.50 per share, raising total gross proceeds of approximately US$75 million to fund ongoing development and commercialization initiatives. This capital raise occurs alongside a settlement with Dr. Reddy's Laboratories that prevents generic competition for Esperion's cholesterol drugs in the U.S. until April 2040, providing more certainty around future revenue streams and exclusivity. We will assess how the successful equity raise, which increases financial resources for R&D and commercialization, impacts Esperion's investment outlook. Uncover the next big thing with financially sound penny stocks that balance risk and reward Esperion Therapeutics Investment Narrative Recap To invest in Esperion Therapeutics, you need to believe in the sustained uptake of its lead cholesterol-lowering drugs, NEXLETOL and NEXLIZET, and the company's ability to translate recent financial progress into profitability. The successful US$75,000,000 equity raise, coupled with a settlemen
Show less
Read more
Impact Snapshot
Event Time:
ESPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ESPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ESPR alerts
High impacting Esperion Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ESPR
News
- Esperion Therapeutics (NASDAQ:ESPR) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.MarketBeat
- Esperion Therapeutics (NASDAQ:ESPR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $9.00 price target on the stock.MarketBeat
- Why Analysts Are Rewriting Esperion's Story After New Pipeline Results and Global Partnerships [Yahoo! Finance]Yahoo! Finance
- Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of HypercholesterolemiaGlobeNewswire
- Esperion to Participate in Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
ESPR
Earnings
- 11/6/25 - Miss
ESPR
Sec Filings
- 11/17/25 - Form 3
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form SCHEDULE
- ESPR's page on the SEC website